Personalis Q4 revenue slightly misses expectations

Overview

• Genomics company's Q4 revenue slightly missed analyst expectations

• Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests

• Secured Medicare coverage for breast and lung cancer surveillance

Outlook

• Personalis expects full-year 2026 revenue between $78 mln and $80 mln

• Clinical revenue for 2026 projected at $10 mln to $11 mln

• Company anticipates clinical test volume of 43,000 to 45,000 tests in 2026

Result Drivers

• CLINICAL TEST VOLUME - Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests, and full year increased nearly 400% to 16,233 tests

Company press release: ID:nBw6CbNYFa

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Personalis Inc is $11.00, about 32.4% above its February 25 closing price of $8.31

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)